Grufity logo
Grufity logo
ZOM

ZOM - Zomedica Pharmaceuticals Corp Stock Price, Fair Value and News

$2.390.00 (0.00%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

11/100

ZOM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

ZOM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ZOM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ZOM Price Action

Last 7 days

-5.5%

Last 30 days

-26.0%

Last 90 days

-53.1%

Trailing 12 Months

8466.7%

ZOM RSI Chart

ZOM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ZOM Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-103.71

Price/Sales (Trailing)

68.22

EV/EBITDA

-112.64

Price/Free Cashflow

-141.05

ZOM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ZOM Fundamentals

ZOM Revenue

Revenue (TTM)

34.3M

Rev. Growth (Yr)

35.37%

Rev. Growth (Qtr)

-15.97%

ZOM Earnings

Earnings (TTM)

-22.6M

Earnings Growth (Yr)

92.89%

Earnings Growth (Qtr)

-0.09%

ZOM Profitability

Operating Margin

66.29%

EBT Margin

-66.31%

Return on Equity

-20.36%

Return on Assets

-18.58%

Free Cashflow Yield

-0.71%

ZOM Investor Care

Buy Backs (1Y)

0%

Diluted EPS (TTM)

-0.01

ZOM Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202634.3M---
202527.5M28.4M29.5M32.0M
202426.0M26.1M26.7M27.3M
202320.7M22.4M24.0M25.2M
20227.8M11.5M15.2M18.9M
2021---4.1M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Zomedica Pharmaceuticals Corp

ZOM
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
 CEO
 WEBSITEzomedica.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES85

Zomedica Pharmaceuticals Corp Frequently Asked Questions

ZOM is the stock ticker symbol of Zomedica Pharmaceuticals Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Zomedica Pharmaceuticals Corp is 2.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, ZOM's PE ratio (Price to Earnings) is -103.71 and Price to Sales (PS) ratio is 68.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZOM PE ratio will change depending on the future growth rate expectations of investors.